BRPI0817542A2 - NOVOS INIBIDORES DE sEH E SEU USO - Google Patents

NOVOS INIBIDORES DE sEH E SEU USO

Info

Publication number
BRPI0817542A2
BRPI0817542A2 BRPI0817542-0A2A BRPI0817542A BRPI0817542A2 BR PI0817542 A2 BRPI0817542 A2 BR PI0817542A2 BR PI0817542 A BRPI0817542 A BR PI0817542A BR PI0817542 A2 BRPI0817542 A2 BR PI0817542A2
Authority
BR
Brazil
Prior art keywords
seh inhibitors
new
new seh
inhibitors
seh
Prior art date
Application number
BRPI0817542-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Yun Ding
Reema K Thalji
Joseph Paul Marino Jr
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0817542A2 publication Critical patent/BRPI0817542A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0817542-0A2A 2007-10-11 2008-10-10 NOVOS INIBIDORES DE sEH E SEU USO BRPI0817542A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
PCT/US2008/079517 WO2009049157A1 (en) 2007-10-11 2008-10-10 Novel seh inhibitors and their use

Publications (1)

Publication Number Publication Date
BRPI0817542A2 true BRPI0817542A2 (pt) 2014-10-07

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817542-0A2A BRPI0817542A2 (pt) 2007-10-11 2008-10-10 NOVOS INIBIDORES DE sEH E SEU USO

Country Status (28)

Country Link
US (2) US8173805B2 (https=)
EP (1) EP2214487B1 (https=)
JP (1) JP5372943B2 (https=)
KR (1) KR101546111B1 (https=)
CN (1) CN101896065B (https=)
AU (1) AU2008310732B2 (https=)
BR (1) BRPI0817542A2 (https=)
CA (1) CA2702265C (https=)
CO (1) CO6270285A2 (https=)
CR (1) CR11423A (https=)
CY (1) CY1114865T1 (https=)
DK (1) DK2214487T3 (https=)
DO (1) DOP2010000101A (https=)
EA (1) EA018414B1 (https=)
ES (1) ES2445444T3 (https=)
HR (1) HRP20140105T1 (https=)
IL (1) IL204889A (https=)
MA (1) MA31761B1 (https=)
MX (1) MX2010003942A (https=)
MY (1) MY157116A (https=)
NZ (1) NZ584471A (https=)
PL (1) PL2214487T3 (https=)
PT (1) PT2214487E (https=)
RS (1) RS53180B (https=)
SI (1) SI2214487T1 (https=)
UA (1) UA107444C2 (https=)
WO (1) WO2009049157A1 (https=)
ZA (1) ZA201002465B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994317B2 (en) 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015104422A1 (en) 2014-01-13 2015-07-16 Basf Se Dihydrothiophene compounds for controlling invertebrate pests
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020074549A1 (en) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
EP4618985A1 (en) 2022-11-18 2025-09-24 Universitat De Barcelona Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
WO2026058000A2 (en) 2024-09-13 2026-03-19 Ucl Business Ltd Methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) * 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
EP1790344B1 (en) * 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CA2449486A1 (en) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
EP1505972A2 (en) 2002-05-16 2005-02-16 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1638955A2 (en) * 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
WO2006037117A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
EP1831181A2 (en) 2004-12-14 2007-09-12 Vertex Pharmaceuticals Incorporated Pyrimidine inhibitors of erk protein kinase and uses thereof
WO2006121719A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
CA2622754A1 (en) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US7994317B2 (en) * 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049154A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
JPWO2009048154A1 (ja) 2007-10-12 2011-02-24 日本電気株式会社 半導体装置及びその設計方法
WO2009070497A1 (en) 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
EP2224928A4 (en) 2007-12-06 2012-02-15 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
WO2009097474A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
EP2240025A4 (en) * 2008-01-30 2012-03-28 Glaxosmithkline Llc NEW SEE INHIBITORS AND THEIR USE
WO2009097476A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
WO2010011917A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS

Also Published As

Publication number Publication date
EA018414B1 (ru) 2013-07-30
UA107444C2 (uk) 2015-01-12
CN101896065A (zh) 2010-11-24
ZA201002465B (en) 2010-12-29
ES2445444T3 (es) 2014-03-03
US20100249137A1 (en) 2010-09-30
EA201070442A1 (ru) 2010-10-29
JP5372943B2 (ja) 2013-12-18
IL204889A0 (en) 2010-11-30
MX2010003942A (es) 2010-04-30
US8173805B2 (en) 2012-05-08
NZ584471A (en) 2012-01-12
HRP20140105T1 (hr) 2014-03-14
AU2008310732B2 (en) 2012-03-08
CA2702265C (en) 2014-12-02
EP2214487B1 (en) 2013-11-27
DOP2010000101A (es) 2010-07-31
CA2702265A1 (en) 2009-04-16
US8212032B2 (en) 2012-07-03
CO6270285A2 (es) 2011-04-20
CN101896065B (zh) 2013-12-18
HK1141211A1 (en) 2010-11-05
RS53180B (sr) 2014-06-30
MA31761B1 (fr) 2010-10-01
CR11423A (es) 2010-06-28
WO2009049157A1 (en) 2009-04-16
CY1114865T1 (el) 2016-12-14
AU2008310732A1 (en) 2009-04-16
SI2214487T1 (sl) 2014-03-31
JP2011500594A (ja) 2011-01-06
PT2214487E (pt) 2014-02-20
EP2214487A1 (en) 2010-08-11
EP2214487A4 (en) 2011-12-21
DK2214487T3 (da) 2014-02-10
PL2214487T3 (pl) 2014-04-30
US20100210656A1 (en) 2010-08-19
KR20100075619A (ko) 2010-07-02
IL204889A (en) 2014-08-31
MY157116A (en) 2016-05-13
KR101546111B1 (ko) 2015-08-20

Similar Documents

Publication Publication Date Title
BRPI0817542A2 (pt) NOVOS INIBIDORES DE sEH E SEU USO
BRPI0821027A2 (pt) 4-(4-ciano-2-tioaril) dihidropirimidinonas e seu uso
BRPI0814963A2 (pt) Pró-fármacos de dipeptóides e seu uso
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0814694A2 (pt) novas esterases e seu uso
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
CR20130360A (es) Compuesto heterocíclico y su uso
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0914595A2 (pt) material substituto de madeira e seu uso
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
BRPI0710878A2 (pt) Compostos orgânicos e seus usos
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
BRPI0907365A2 (pt) Composição antimicrobiana e uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time